NASDAQ Framework: TransMedics Group Inc.

Medical technology company transforming organ transplant therapy 1.

TransMedics Group, Inc., founded in 1998 and headquartered in Andover, Massachusetts, is a commercial-stage medical technology company that focuses on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The company has developed the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that replicates near-physiologic conditions for donor organs outside the human body, addressing the limitations of cold storage. TransMedics offers OCS LUNG, OCS Heart, and OCS Liver for the preservation and functional monitoring of donor organs, and has also developed a national OCS program to provide comprehensive organ management and logistics services 2 3 4.

2: TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. View Source3: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. View Source4: TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA. View Source

UNKNOWN

While the provided facts indicate that Waleed H. Hassanein, the founder of TransMedics Group Inc., is currently the President and CEO 5 6, there is no information confirming whether other founders are still involved or heavily involved in the company's operations.

5: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 3.49 percent of Transmedics Group Inc shares are owned by insiders, and 105.45 percent are held by financial institutions. Khayal Tamer I, the Chief Commercial Officer at Transmedics Group Inc (TMDX) has sold 2,958 shares of firm on Jul 01 ’24 at a price of $151.40 against the total amount of $0.45 million. In another inside trade, Hassanein Waleed H, President & CEO of Transmedics Group Inc (NASDAQ:TMDX) sold 8,625 shares of the firm on Jun 14 ’24 for a total worth of $1.22 million at a price of $141.85. An inside trade which took place on Jun 05 ’24, Director of Transmedics Group Inc Basile Edward M sold 1,193 shares of firm against total price of $0.16 million at the cost of $138.08 per share. View Source6: TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA. View Source

MEDIUM RISK

TransMedics Group Inc. is currently in a transitional phase as it is on the verge of shifting from loss to profit, with analysts expecting the company to generate positive profits of US$34m in 2024 7. However, the company has a significant debt-to-equity ratio of over 2x, which is considerably higher than the recommended threshold of 40% 8. This high level of debt increases the financial risk, particularly for a company that has not yet consistently achieved profitability. While the company's recent financial performance shows strong growth, including a 104% rally in Q2 2024 9, the substantial debt burden and the need to achieve aggressive growth targets to meet profitability estimates contribute to a medium risk assessment.

7: Consensus from 9 of the American Medical Equipment analysts is that TransMedics Group is on the verge of breakeven. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$34m in 2024. Therefore, the company is expected to breakeven roughly 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 42%, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. View Source8: Before we wrap up, there’s one issue worth mentioning. TransMedics Group currently has a debt-to-equity ratio of over 2x. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, which in this case, the company has significantly overshot. Note that a higher debt obligation increases the risk around investing in the loss-making company. View Source9: TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 15, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 9,522 shares of its common stock and an aggregate of 6,240 restricted stock units to 5 employees, each as a material inducement for each employee's entry into employment with TransMedics. The gr PR Newswire • 3 days ago TMDX +1.94% TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. PR Newswire • 4 days ago TMDX +1.94% TransMedics (TMDX) Moves to Buy: Rationale Behind the Upgrade TransMedics (TMDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Zacks • 5 days ago TMDX +1.94% TransMedics (TMDX) Rallied 104% in Q2 Headwaters Capital Management, an investment management company, released its second-quarter 2024 investor letter. A copy of the letter can be downloaded here. It was a calm period for the market compared to the last three years. The fund returned +1.3% (+1.1% net) in the second quarter compared to a -3.4% fall for the Russell Mid […] Insider Monkey • 8 days ago TMDX +1.94% 3 Breakthrough Medical Device Stocks to Invest In Now Medical device stocks are effectively redefining the healthcare industry through innovative technology. The digitization trend in healthcare continues gaining steam, with advanced medical devices enhancing healthcare outcomes while becoming critical drivers in driving financial markets. These tools offer accurate diagnoses, effective treatments, and personalized care, improving healthcare outcomes substantially. Hence, given their potential to revolutionize patient care, these devices will conti InvestorPlace • 13 days ago ISRG TMDX +1.94% DXCM Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 These healthcare stocks have clear paths to growth over the next few years. Motley Fool • 23 days ago TMDX +1.94% VRTX VKTX TransMedics Group, Inc. (NASDAQ:TMDX) About To Shift From Loss To Profit We feel now is a pretty good time to analyse TransMedics Group, Inc.'s ( NASDAQ:TMDX ) business as it appears the... Simply Wall St. • 25 days ago TMDX +1.94% The 3 Best Medical Device Stocks to Buy in June 2024 Medical devices are spearheading the digitalization of healthcare, reports analytics and software development company Luxoft. Specifically, medical devices are “providing accurate diagnoses, effective treatments and personalized care through advanced algorithms and patient data analysis.” Moreover, artificial intelligence (AI) is altering and improving the means by which many medical devices are created and work. Indeed, by quickly creating many prototypes based on design parameters and patient InvestorPlace • last month ISRG TMDX +1.94% UTHR TransMedics (TMDX) Just Reclaimed the 20-Day Moving Average When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react? Zacks • last month TMDX +1.94% Insider Sale: Director Edward Basile Sells Shares of TransMedics Group Inc (TMDX) Director Edward Basile of TransMedics Group Inc (NASDAQ:TMDX) sold 1,193 shares of the company on June 5, 2024, according to a recent SEC Filing. GuruFocus.com • last month TMDX +1.94% Insider Sale: Director David Weill Sells Shares of TransMedics Group Inc (TMDX) On May 29, 2024, David Weill, Director at TransMedics Group Inc (NASDAQ:TMDX), executed a sale of 1,193 shares of the company. GuruFocus.com • last month TMDX +1.94% The 3.9% return this week takes TransMedics Group's (NASDAQ:TMDX) shareholders three-year gains to 460% For us, stock picking is in large part the hunt for the truly magnificent stocks. Mistakes are inevitable, but a single... Simply Wall St. • last month TMDX +1.94% Are You Looking for a Top Momentum Pick? Why TransMedics (TMDX) is a Great Choice Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out. Zacks • 2 months ago TMDX +1.94% Is Trending Stock TransMedics Group, Inc. (TMDX) a Buy Now? Zacks.com users have recently been watching TransMedics (TMDX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. Zacks • 2 months ago TMDX +1.94% TransMedics Group, Inc. (NASDAQ:TMDX) Q1 2024 Earnings Call Transcript TransMedics Group, Inc. (NASDAQ:TMDX) Q1 2024 Earnings Call Transcript May 1, 2024 TransMedics Group, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the TransMedics First Quarter 2024 Earnings Conference Call. At this time, all […] Insider Monkey • 2 months ago TMDX +1.94% Will TransMedics (TMDX) Gain on Rising Earnings Estimates? TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. Zacks • 2 months ago TMDX +1.94% ^GSPC TransMedics Group, Inc. (TMDX) Soars to 52-Week High, Time to Cash Out? TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. Zacks • 2 months ago TMDX +1.94% Should You Think About Buying TransMedics Group, Inc. (NASDAQ:TMDX) Now? TransMedics Group, Inc. ( NASDAQ:TMDX ), is not the largest company out there, but it led the NASDAQGM gainers with a... Simply Wall St. • 2 months ago TMDX +1.94% TransMedics Group First Quarter 2024 Earnings: Beats Expectations TransMedics Group ( NASDAQ:TMDX ) First Quarter 2024 Results Key Financial Results Revenue: US$96.9m (up 133% from 1Q... Simply Wall St. • 2 months ago TMDX +1.94% Is TransMedics (TMDX) a Buy as Wall Street Analysts Look Optimistic? According to the average brokerage recommendation (ABR), one should invest in TransMedics (TMDX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? Zacks • 2 months ago TMDX +1.94% View Source

NO

There is no evidence in the provided facts indicating that TransMedics Group Inc. is launching any new product offerings. The information focuses on their existing products, financial performance, and stock activities.

TransMedics Group Inc. has demonstrated remarkable growth and is poised for further expansion from 2024 through 2026. The company is on the cusp of shifting from loss to profit, with analysts projecting positive profits of US$34 million in 2024 10. This transition is supported by their innovative Organ Care System (OCS), which includes OCS LUNG, OCS Heart, and OCS Liver for the preservation and functional monitoring of donor organs 11. Additionally, TransMedics has developed a national OCS program to provide comprehensive organ management and logistics services 12. The company aims to sustain an aggressive annual growth rate of 42% to meet these profitability targets 13, indicating a robust expansion strategy focused on enhancing their existing product offerings and operational capabilities.

10: Consensus from 9 of the American Medical Equipment analysts is that TransMedics Group is on the verge of breakeven. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$34m in 2024. Therefore, the company is expected to breakeven roughly 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 42%, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. View Source11: TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. View Source12: TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. View Source13: Consensus from 9 of the American Medical Equipment analysts is that TransMedics Group is on the verge of breakeven. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$34m in 2024. Therefore, the company is expected to breakeven roughly 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 42%, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. View Source

Sources

1: TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. View Source2: TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. View Source3: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. View Source4: TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA. View Source5: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 3.49 percent of Transmedics Group Inc shares are owned by insiders, and 105.45 percent are held by financial institutions. Khayal Tamer I, the Chief Commercial Officer at Transmedics Group Inc (TMDX) has sold 2,958 shares of firm on Jul 01 ’24 at a price of $151.40 against the total amount of $0.45 million. In another inside trade, Hassanein Waleed H, President & CEO of Transmedics Group Inc (NASDAQ:TMDX) sold 8,625 shares of the firm on Jun 14 ’24 for a total worth of $1.22 million at a price of $141.85. An inside trade which took place on Jun 05 ’24, Director of Transmedics Group Inc Basile Edward M sold 1,193 shares of firm against total price of $0.16 million at the cost of $138.08 per share. View Source6: TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA. View Source7: Consensus from 9 of the American Medical Equipment analysts is that TransMedics Group is on the verge of breakeven. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$34m in 2024. Therefore, the company is expected to breakeven roughly 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 42%, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. View Source8: Before we wrap up, there’s one issue worth mentioning. TransMedics Group currently has a debt-to-equity ratio of over 2x. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, which in this case, the company has significantly overshot. Note that a higher debt obligation increases the risk around investing in the loss-making company. View Source9: TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 15, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 9,522 shares of its common stock and an aggregate of 6,240 restricted stock units to 5 employees, each as a material inducement for each employee's entry into employment with TransMedics. The gr PR Newswire • 3 days ago TMDX +1.94% TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. PR Newswire • 4 days ago TMDX +1.94% TransMedics (TMDX) Moves to Buy: Rationale Behind the Upgrade TransMedics (TMDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Zacks • 5 days ago TMDX +1.94% TransMedics (TMDX) Rallied 104% in Q2 Headwaters Capital Management, an investment management company, released its second-quarter 2024 investor letter. A copy of the letter can be downloaded here. It was a calm period for the market compared to the last three years. The fund returned +1.3% (+1.1% net) in the second quarter compared to a -3.4% fall for the Russell Mid […] Insider Monkey • 8 days ago TMDX +1.94% 3 Breakthrough Medical Device Stocks to Invest In Now Medical device stocks are effectively redefining the healthcare industry through innovative technology. The digitization trend in healthcare continues gaining steam, with advanced medical devices enhancing healthcare outcomes while becoming critical drivers in driving financial markets. These tools offer accurate diagnoses, effective treatments, and personalized care, improving healthcare outcomes substantially. Hence, given their potential to revolutionize patient care, these devices will conti InvestorPlace • 13 days ago ISRG TMDX +1.94% DXCM Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 These healthcare stocks have clear paths to growth over the next few years. Motley Fool • 23 days ago TMDX +1.94% VRTX VKTX TransMedics Group, Inc. (NASDAQ:TMDX) About To Shift From Loss To Profit We feel now is a pretty good time to analyse TransMedics Group, Inc.'s ( NASDAQ:TMDX ) business as it appears the... Simply Wall St. • 25 days ago TMDX +1.94% The 3 Best Medical Device Stocks to Buy in June 2024 Medical devices are spearheading the digitalization of healthcare, reports analytics and software development company Luxoft. Specifically, medical devices are “providing accurate diagnoses, effective treatments and personalized care through advanced algorithms and patient data analysis.” Moreover, artificial intelligence (AI) is altering and improving the means by which many medical devices are created and work. Indeed, by quickly creating many prototypes based on design parameters and patient InvestorPlace • last month ISRG TMDX +1.94% UTHR TransMedics (TMDX) Just Reclaimed the 20-Day Moving Average When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react? Zacks • last month TMDX +1.94% Insider Sale: Director Edward Basile Sells Shares of TransMedics Group Inc (TMDX) Director Edward Basile of TransMedics Group Inc (NASDAQ:TMDX) sold 1,193 shares of the company on June 5, 2024, according to a recent SEC Filing. GuruFocus.com • last month TMDX +1.94% Insider Sale: Director David Weill Sells Shares of TransMedics Group Inc (TMDX) On May 29, 2024, David Weill, Director at TransMedics Group Inc (NASDAQ:TMDX), executed a sale of 1,193 shares of the company. GuruFocus.com • last month TMDX +1.94% The 3.9% return this week takes TransMedics Group's (NASDAQ:TMDX) shareholders three-year gains to 460% For us, stock picking is in large part the hunt for the truly magnificent stocks. Mistakes are inevitable, but a single... Simply Wall St. • last month TMDX +1.94% Are You Looking for a Top Momentum Pick? Why TransMedics (TMDX) is a Great Choice Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out. Zacks • 2 months ago TMDX +1.94% Is Trending Stock TransMedics Group, Inc. (TMDX) a Buy Now? Zacks.com users have recently been watching TransMedics (TMDX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. Zacks • 2 months ago TMDX +1.94% TransMedics Group, Inc. (NASDAQ:TMDX) Q1 2024 Earnings Call Transcript TransMedics Group, Inc. (NASDAQ:TMDX) Q1 2024 Earnings Call Transcript May 1, 2024 TransMedics Group, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the TransMedics First Quarter 2024 Earnings Conference Call. At this time, all […] Insider Monkey • 2 months ago TMDX +1.94% Will TransMedics (TMDX) Gain on Rising Earnings Estimates? TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. Zacks • 2 months ago TMDX +1.94% ^GSPC TransMedics Group, Inc. (TMDX) Soars to 52-Week High, Time to Cash Out? TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. Zacks • 2 months ago TMDX +1.94% Should You Think About Buying TransMedics Group, Inc. (NASDAQ:TMDX) Now? TransMedics Group, Inc. ( NASDAQ:TMDX ), is not the largest company out there, but it led the NASDAQGM gainers with a... Simply Wall St. • 2 months ago TMDX +1.94% TransMedics Group First Quarter 2024 Earnings: Beats Expectations TransMedics Group ( NASDAQ:TMDX ) First Quarter 2024 Results Key Financial Results Revenue: US$96.9m (up 133% from 1Q... Simply Wall St. • 2 months ago TMDX +1.94% Is TransMedics (TMDX) a Buy as Wall Street Analysts Look Optimistic? According to the average brokerage recommendation (ABR), one should invest in TransMedics (TMDX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? Zacks • 2 months ago TMDX +1.94% View Source10: Consensus from 9 of the American Medical Equipment analysts is that TransMedics Group is on the verge of breakeven. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$34m in 2024. Therefore, the company is expected to breakeven roughly 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 42%, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. View Source11: TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. View Source12: TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. View Source13: Consensus from 9 of the American Medical Equipment analysts is that TransMedics Group is on the verge of breakeven. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$34m in 2024. Therefore, the company is expected to breakeven roughly 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 42%, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. View Source